EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

GAITHERSBURG, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, October 29, 2025, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2025.

Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the page of Emergent’s website.

About Emergent BioSolutions 

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our  and follow us on , , ,  and . 

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

Media Contact:

Assal Hellmer

Vice President, Communications



EN
08/10/2025

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financ...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Ad...

42m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Progr...

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were able to return value t...

46m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Approximately $140 Million in Contract...

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately...

46m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. T...

February 12, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Fina...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive ...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch